No abstract

A selective reversed phase high performance liquid chromatography/photodiode array detector (RP-HPLC/PAD) method has been developed for simultaneous determination of the three co-administrated deflazacort, aprepitant and granisetron drugs used with chemotherapy. The three cited drugs have been chromatographed on C18 column using a mobile phase consisting of acetonitrile–0.2% v/v triethylamine (80:20 v/v, pH of 6.6 ± 0.05) with isocratic elution and monitored by photodiode array at 220 nm. International conference on harmonization (ICH) guidelines were followed to validate the developed method. Successful application of the developed method was assessed by the simultaneous determination of the studied drugs in pure forms, dosage forms and plasma samples in the ranges of 0.2–20, 0.4–40 and 0.2–20 μg/mL for deflazacort, aprepitant and granisetron, respectively.

This paper presents a novel potentiometric approach for the determination of palonosetron HCl using two sensors; ionophore-free and ionophore-doped ones. The two sensors successfully determined the cited drug in the range of 1 × 10–5–1 × 10–2 M with respective Nernstian slopes of 54.9 ± 0.25 and 59.3 ± 0.16 mV/decade. Incorporating calix[8]arene as an ionophore resulted in a lower detection limit (LOD = 3.1 × 10–6 M) and enhanced selectivity when compared to the ionophore-free sensor (LOD = 7.9 × 10–6 M). This modification was also associated with faster response for the ionophore-doped sensor (response time = 20 s) compared to the ionophore-free one (response time = 30 s). The two sensors showed a stable response over a pH range of 3.0–8.0. They successfully determined palonosetron HCl in presence of its oxidative degradation products. They were also used for direct determination of the drug in commercially available parenteral solution without any interference from other dosage forms’ additives.

No abstract